Document is current
Any future updates will be listed below
-
Authors
Matsuda, Satoru
Takeuchi, Hiroya
Kato, Ken
Machida, Ryunosuke
Ito, Yoshinori
Tsubosa, Yasuhiro
Daiko, Hiroyuki
Koyanagi, Kazuo
Ogata, Takashi
Fukuda, Takashi
Fujita, Takeo
Abe, Tetsuya
Bamba, Takeo
Watanabe, Masayuki
Kawakubo, Hirofumi
Shibuya, Yuichi
Otsubo, Dai
Kakisita, Tomokazu
Hashimoto, Tadayoshi
Sasaki, Keita
Kitagawa, Yuko
- License Information
-
More Information
Article History
Received: 3 July 2024
Accepted: 20 September 2024
First Online: 7 October 2024
Disclosures
: K.K. reports funding to the institution from Merck Sharp & Dohme Corp, Ono Pharmaceuticals, Bristol Myers Squibb, Beigene, Shionogi, Merck Biopharma, Oncolys BioPharma, Daiichi Sankyo, Novartis, Taiho Pharmaceutical, Janssen, AstraZeneca, and Chugai. Y.K. declares relevant financial activities outside the submitted work related to CHUGAI PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD, ASAHI KASEI PHARMA CORPORATION, Otsuka Pharmaceutical Co., Ltd., TSUMURA & CO., KAKEN PHARMACEUTICAL CO., LTD., Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Factory Inc., Kyouwa Hakkou Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., TEIJIN PHARMA LIMITED, Kowa Company, Ltd., ASAHI KASEI PHARMA CORPORATION, AstraZeneca K.K., Ethicon Inc., ONO PHARMACEUTICAL CO., LTD, Otsuka Pharmaceutical Factory, Inc., Olympus Corporation Cardinal Health K.K., SHIONOGI & CO., LTD, TAIHO PHARMACEUTICAL CO., LTD, CHUGAI PHARMACEUTICAL CO., LTD, Bristol-Myers Squibb K.K., MSD K.K., Smith & Nephew KK, KAKEN PHARMACEUTICAL CO.,LTD., ASKA Pharmaceutical Co., Ltd., MIYARISAN PHARMACEUTICAL CO. LTD., Toray Industries, Inc., DAIICHI SANKYO COMPANY, LIMITED, Chugai Foundation for Innovative Drug Discovery Science, Nippon Kayaku Co., Ltd., EA Pharma Co., Ltd., Intuitive Surgical G.K., Takeda Pharmaceutical Company Limited, SYSMEX CORPORATION, TSUMURA & CO., AI Medical Service Inc., Kowa Company, Ltd., and Eisai Co., Ltd.
